000132856 001__ 132856
000132856 005__ 20240229105035.0
000132856 0247_ $$2doi$$a10.1186/s13550-018-0383-7
000132856 0247_ $$2pmid$$apmid:29633046
000132856 0247_ $$2pmc$$apmc:PMC5891438
000132856 037__ $$aDKFZ-2018-00499
000132856 041__ $$aeng
000132856 082__ $$a610
000132856 1001_ $$00000-0001-8739-8741$$aSachpekidis, C.$$b0$$eFirst author
000132856 245__ $$aAssessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging.
000132856 260__ $$aBerlin$$bSpringer$$c2018
000132856 3367_ $$2DRIVER$$aarticle
000132856 3367_ $$2DataCite$$aOutput Types/Journal article
000132856 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660127777_9237
000132856 3367_ $$2BibTeX$$aARTICLE
000132856 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132856 3367_ $$00$$2EndNote$$aJournal Article
000132856 520__ $$aDespite the significant upgrading in recent years of the role of 18F-FDG PET/CT in multiple myeloma (MM) diagnostics, there is a still unmet need for myeloma-specific radiotracers. 3-Deoxy-3-[18F]fluorothymidine (18F-FLT) is the most studied cellular proliferation PET agent, considered a potentially new myeloma functional imaging tracer. The aim of this pilot study was to evaluate 18F-FLT PET/CT in imaging of MM patients, in the context of its combined use with 18F-FDG PET/CT.Eight patients, four suffering from symptomatic MM and four suffering from smoldering MM (SMM), were enrolled in the study. All patients underwent 18F-FDG PET/CT and 18F-FLT PET/CT imaging by means of static (whole body) and dynamic PET/CT of the lower abdomen and pelvis (dPET/CT) in two consecutive days. The evaluation of PET/CT studies was based on qualitative evaluation, semi-quantitative (SUV) calculation, and quantitative analysis based on two-tissue compartment modeling. 18F-FDG PET/CT demonstrated focal, 18F-FDG avid, MM-indicative bone marrow lesions in five patients. In contrary, 18F-FLT PET/CT showed focal, 18F-FLT avid, myeloma-indicative lesions in only two patients. In total, 48 18F-FDG avid, focal, MM-indicative lesions were detected with 18F-FDG PET/CT, while 17 18F-FLT avid, focal, MM-indicative lesions were detected with 18F-FLT PET/CT. The number of myeloma-indicative lesions was significantly higher for 18F-FDG PET/CT than for 18F-FLT PET/CT. A common finding was a mismatch of focally increased 18F-FDG uptake and reduced 18F-FLT uptake (lower than the surrounding bone marrow). Moreover, 18F-FLT PET/CT was characterized by high background activity in the bone marrow compartment, further complicating the evaluation of bone marrow lesions. Semi-quantitative evaluation revealed that both SUVmean and SUVmax were significantly higher for 18F-FLT than for 18F-FDG in both MM lesions and reference tissue. SUV values were higher in MM lesions than in reference bone marrow for both tracers.Despite the limited number of patients analyzed in this pilot study, the first results of the trial indicate that 18F-FLT does not seem suitable as a single tracer in MM diagnostics. Further studies with a larger patient population are warranted to generalize the herein presented results.
000132856 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000132856 588__ $$aDataset connected to CrossRef, PubMed,
000132856 7001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, H.$$b1$$udkfz
000132856 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, K.$$b2
000132856 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, A.$$b3
000132856 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b4$$eLast author
000132856 773__ $$0PERI:(DE-600)2619892-7$$a10.1186/s13550-018-0383-7$$gVol. 8, no. 1, p. 28$$n1$$p28$$tEJNMMI Research$$v8$$x2191-219X$$y2018
000132856 909CO $$ooai:inrepo02.dkfz.de:132856$$pVDB
000132856 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-8739-8741$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132856 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000132856 9141_ $$y2018
000132856 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEJNMMI RES : 2015
000132856 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132856 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132856 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132856 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132856 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132856 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132856 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132856 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132856 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132856 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000132856 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x1
000132856 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132856 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000132856 980__ $$ajournal
000132856 980__ $$aVDB
000132856 980__ $$aI:(DE-He78)E060-20160331
000132856 980__ $$aI:(DE-He78)E030-20160331
000132856 980__ $$aI:(DE-He78)L101-20160331
000132856 980__ $$aI:(DE-He78)C060-20160331
000132856 980__ $$aUNRESTRICTED